Sotorasib versus docetaxel: evidence supporting CodeBreaK 200.

IF 41.6 1区医学 Q1 ONCOLOGY

Lancet Oncology Pub Date : 2024-08-01 DOI:10.1016/S1470-2045(24)00388-7

Luis Paz-Ares, Bhakti Mehta, Yang Wang, David Waterhouse, Adrianus Johannes de Langen

引用次数: 0

查看原文本刊更多论文

索托拉西布与多西他赛：支持 CodeBreaK 200 的证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Lancet Oncology 医学-肿瘤学

CiteScore

62.10

自引率

1.00%

发文量

913

审稿时长

3-8 weeks

期刊介绍： The Lancet Oncology is a trusted international journal that addresses various topics in clinical practice, health policy, and global oncology. It covers a wide range of cancer types, including breast, endocrine system, gastrointestinal, genitourinary, gynaecological, haematological, head and neck, neurooncology, paediatric, thoracic, sarcoma, and skin cancers. Additionally, it includes articles on epidemiology, cancer prevention and control, supportive care, imaging, and health-care systems. The journal has an Impact Factor of 51.1, making it the leading clinical oncology research journal worldwide. It publishes different types of articles, such as Articles, Reviews, Policy Reviews, Personal Views, Clinical Pictures, Comments, Correspondence, News, and Perspectives. The Lancet Oncology also collaborates with societies, governments, NGOs, and academic centers to publish Series and Commissions that aim to drive positive changes in clinical practice and health policy in areas of global oncology that require attention.